The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | ICARIA-MM: final OS analysis
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares the results of the final analysis of the ICARIA-MM study (NCT02990338) which compares isatuximab, pomalidomide, and dexamethasone to pomalidomide and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. The study showed a sustained progression-free survival (PFS) benefit as well as a strong trend toward a survival benefit for patients treated with the triplet combination, thereby supporting the use of isatuximab, pomalidomide and dexamethasone in the R/R setting. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
